Healthcare ETFs To Buy On Solid Q2 Earnings Expectations

Merck is expected to report results on Jul 27 before the market opens. It has a Zacks Rank #3 and an Earnings ESP of -1.13%. The stock delivered a positive earnings surprise in the last four quarters, with an average beat of 8.55% and witnessed positive earnings estimate revision of a penny over the past 30 days for the to-be-reported quarter. Merck has a VGM Score of D.

Amgen carries a Zacks Rank #3 and has an Earnings ESP of +1.46%, indicating a reasonable chance of beating estimates this time around. The earnings surprise track over the past four quarters is strong, with an average positive surprise of 3.54%. Amgen has witnessed no earnings estimate revision over the past 30 days for the quarter to be reported. The stock has a solid VGM Score of A. Amgen will report earnings on Jul 26 after market close.

AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.15%. The company delivered a positive earnings surprise in the last four quarters, with an average beat of 2.39% and has seen no earnings estimate revision over the past month for the to-be-reported quarter. The stock has a solid VGM Score of A. The company is scheduled to report on Jul 27 before the opening bell.    

Gilead is expected to release earnings on Jul 25 after market close. It has a Zacks Rank #2 and an Earnings ESP of +0.15%, indicating a higher chance of beating estimates this quarter. Gilead delivered positive earnings surprises of 4.98% over the last four quarters and has seen positive earnings estimate revision of three cents over the past month for the to-be-reported quarter. It has a VGM Score of D.

Bristol-Myers will likely report earnings on Jul 26 before the opening bell. It has a Zacks Rank #3 and an Earnings ESP of +0.79%. The stock delivered an average positive earnings surprise of 2.71% over the past four quarters and witnessed no earnings estimate revision for the to-be-reported quarter in a month. It flaunts a top VGM Score of A.

Summing Up

With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs. In particular, all the four ETFs have a Zacks ETF Rank #2 .

1 2
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any specific ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.